Patrick Leavey, M.D.
Patrick Leavey graduated from the Royal College of Surgeons in Ireland in 1986. He spent 4 years in Ireland as a junior house officer (Internal Medicine and Pediatrics), 2 years at Princess Margaret Hospital in Perth, Western Australia as a pediatric registrar and then came to the US to do his pediatric hematology/oncology fellowship at The Children’s Hospital Denver and University of Colorado Health Sciences Center in 1992. Dr. Leavey worked in the lab of Daniel Ambruso, M.D. for 4 years on projects related to the influence of G-CSF on granulocyte function and the exploration and identification of a novel neutrophil cytosolic protein.
Dr. Leavey joined the pediatric faculty at UT Southwestern Medical Center in 1998 where he is currently an Associate Professor of Pediatrics and a Pediatric Oncologist at the Children’s Medical Center (CMC) Dallas.
During his years of training Dr. Leavey became a member of the Royal College of Physicians of Ireland, a Fellow of the Royal Australasian College of Physicians and a Diplomate of Child Health from the National University of Ireland. He submitted a thesis based on his work in the lab and was granted a Doctorate in Medicine from the National University of Ireland. He is also subspecialty board certified in Pediatric Hematology/Oncology by the American Board of Pediatrics.
Currently Dr. Leavey holds several leadership positions both regionally and nationally in areas of education, research and administration. He is the Associate Medical Director for Clinical Affairs, of the Center for Center and Blood Disorders at Children’s Medical Center Dallas; the Fellowship training Director at the Division of Pediatric Hematology/Oncology at UT Southwestern Medical Center Dallas, the Chair for the Training Committee at the American Society of Pediatric Hematology/Oncology and a member of the Executive Committee of the Council of Pediatric Subspecialties; and the Co-Chair for the international AEWS1031 study for newly diagnosed patients with non-metastatic Ewing Sarcoma at the Children’s Oncology Group.
|Medical School||Royal College of Surgeons (1986)|
|Internship||Beaumont Hospital-Dublin, Ireland (1987), Surgery|
|Residency||St. Vincents Hospital - Dublin Ireland (1989), Internal Medicine|
|Fellowship||University of Colorado Health Sciences Center (1996), Pediatric Hematology/oncology|
|Residency||Children's Hospital of Denver (1998), Pediatrics|
Graduate Medical Changes: Yes We Can or Enough Already?
Leavey, P.J.; Jubran, R.F. Pediatr Blood and Cancer 2012 epub ahead of print
IL-8 predicts pediatric oncology patients with febrile neutropenia at low-risk for bacteremia.
Cost C, Stegner MM, Leonard D and Leavey P J Pediatr Hematol/Oncol 2012 epub ahead of print
Comparison of dose intensified versus standard chemotherapy for non-metastatic Ewing Sarcoma Family of Tumors (ESFT): A Children?s Oncology Group Study Report
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Neyssa M, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt C, Sailer S, Marcus KJ, Perlman E, Dickman PS and Grier H. J Clin Oncol 2009 27 15 2536-41
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, Gebhardt M, Grier HE Pediatr Blood Cancer 2008 Sep 51 3 334-8
Leavey PJ, Collier AB Expert Rev Anticancer Ther 2008 Apr 8 4 617-24
Leavey PJ Pediatr Blood Cancer 2012 Nov
How many physicians do we need? A Benchmark for Pediatric Hematology/Oncology
Leavey,P.J. Pediatr Blood and Cancer 2012 epub ahead of print
Predictive value of interleukin-5 and monocyte chemotactic protein-1 (MCP-1) for bactermia in children with febrile neutropenia.
Victor M Aquino VM, Cost C, Gomez A, Bowers DC, Ramilo O, Ahmad N, Winick N, Leavey PJ. J Pediatr Hematol Oncol 2012 34 6 e241-5
Leavey PJ, Timmons C, Frawley W, Lombardi D, Ashfaq R Pediatr. Dev. Pathol. 2006 May-Jun 9 3 219-24
The Prevalence and Use of Anti-depressant Medication (ADM) in Pediatric Cancer Patients.
Portteus A, Ahmad N, Tobey D and Leavey P. J Child Adolesc Psychopharmacol 2006 16/4 467-473